PCVX Live signaler | Maksimer profitt med Getagraph.com

SELG 3740 min ago

@ $60.49

Utstedt: 26 apr 2024 @ 19:03

Avkastning: 0.39%

Forrige signal: apr 26 - 17:21

Forrige signal: Kjøp

Avkastning: 1.30 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	583 957
Gjennomsnittsvolum	865 760
Markedsverdi	6.60B
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $-1.110 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.67
ATR14	$1.533 (2.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Pickering Grant	Buy	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Stock Option (Right to Buy)
2024-04-18	Guggenhime Andrew	Sell	8 000	Stock Option (right to buy)
2024-04-18	Guggenhime Andrew	Buy	8 000	Common Stock

INSIDER POWER
36.03
Last 100 transactions
Buy: 779 468 \| Sell: 362 821

Volum Korrelasjon

Lang: -0.43 (neutral)

Kort: 0.88 (strong)

Signal:(68) Same movement expected

Vaxcyte Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vaxcyte Inc Korrelasjon - Valuta/Råvare

0.31
( neutral )

-0.14
( neutral )

0.00
( neutral )

0.08
( neutral )

-0.40
( neutral )

-0.26
( neutral )

Vaxcyte Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2023
Omsetning:	$0
Bruttogevinst:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2022
Omsetning:	$0
Bruttogevinst:	$-9.20M (0.00 %)
EPS:	$-3.69

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.